Itrancure 100 Capsule contains Itraconazole 100 mg, a broad-spectrum triazole antifungal agent used for the treatment of various fungal infections. Itraconazole exerts its antifungal activity by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. This medication is indicated for the management of systemic and superficial mycoses, including blastomycosis, histoplasmosis, aspergillosis, onychomycosis, and candidiasis. Itrancure 100 Capsule is typically administered orally, with dosing regimens tailored according to the severity and type of infection. It demonstrates excellent bioavailability when taken with food and is extensively metabolized in the liver via the cytochrome P450 system, necessitating caution when co-administered with drugs metabolized by the same pathway due to potential drug interactions. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain, as well as headache and dizziness. Liver function tests should be monitored during prolonged therapy to detect hepatotoxicity. Itrancure 100 Capsule is contraindicated in patients with known hypersensitivity to itraconazole and should be used cautiously in individuals with hepatic impairment or congestive heart failure. It is essential to adhere to prescribed dosages and consult healthcare professionals before initiating therapy.